A Study of Rituximab and Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children with Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and Mature B-Cell Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group

Autor:	Sheila Weitzman, Robert E. Hutchison, Deborah Woods, Bruce Shiramizu, Howard J. Weinstein, Margaret Barnich, Myron Chang, Timothy C. Griffin, Thomas G. Gross, Mitchell S. Cairo, Joseph Wiley
Jazyk:	angličtina
Rok vydání:	2009
Předmět:	Oncology medicine.medical_specialty Lymphoma medicine.medical_treatment Article chemistry.chemical_compound immune system diseases hemic and lymphatic diseases Internal medicine medicine Humans Child Etoposide Chemotherapy Ifosfamide business.industry Antibodies Monoclonal Hematology medicine.disease Carboplatin Non-Hodgkin's lymphoma Leukemia Treatment Outcome chemistry Pediatrics Perinatology and Child Health Rituximab Drug Therapy Combination business medicine.drug
Popis:	Background To estimate the response rate and therapy related toxicities of the anti-CD20 monoclonal antibody rituximab when combined with chemotherapy including ifosfamide, carboplatin, and etoposide (ICE) in patients with relapsed and refractory B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa4a91c4121647d32ab2dcc38a8b8d79 https://europepmc.org/articles/PMC2728935/ Zobrazit plný text záznamu